Detection of behavioral impairments correlated to neurochemical deficits in mice treated with moderate doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Experimental Neurology

Volumn 178, Issue 1, 2002, Pages 80-90

  Tillerson, Jennifer L ^a   Caudle, W Michael ^a   Reverón, Maria E ^a   Miller, Gary W ^a,b  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b Center for Neurodegenerative Disease   (United States)

Author keywords

Behavior; Dopamine; Motor; MPTP; Parkinson's disease; Recovery of function

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARRIER PROTEIN; DOPAMINE; DOPAMINE TRANSPORTER; LEVODOPA; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; DRUG EFFECT; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0036447089     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.8021     Document Type: Article

References (48)

1. Ali, S. F., S. N. David, and G. D. Newport. 1993. Age-related susceptibility to MPTP-induced neurotoxicity in mice. Neurotoxicology 14: 29-34.
2. Ballermann, M., G. A. Metz, J. E. McKenna, F. Klassen, and I. Q. Whishaw. 2001. The pasta matrix reaching task: A simple test for measuring skilled reaching distance, direction, and dexterity in rats. J. Neurosci. Methods 106: 39-45.
3. Barlow, C., S. Hirotsune, R. Paylor, M. Liyanage, M. Eckhaus, F. Collins, Y. Shiloh, J. N. Crawley, T. Ried, D. Tagle, and A. Wynshaw-Boris. 1996. Atm-deficient mice: A paradigm of ataxia telangiectasia. Cell 86: 159-171.
4. Camicioli, R., S. J. Grossmann, P. S. Spencer, K. Hudnell, and W. K. Anger. 2001. Discriminating mild parkinsonism: Methods for epidemiological research. Mov. Disord. 16: 33-40.
5. Clarke, K. A., and J. Still. 2001. Development and consistency of gait in the mouse. Physiol. Behav. 73: 159-164.
6. Colotla, V. A., E. Flores, A. Oscos, A. Meneses, and R. Tapia. 1990. Effects of MPTP on locomotor activity in mice. Neurotoxicol. Teratol. 12: 405-407.
7. Cotzias, G. C., M. H. Van Woert, and L. M. Schiffer. 1967. Aromatic amino acids and modification of parkinsonism. N. Engl. J. Med. 276: 374-379.
8. Crawley, J. N. 1999. Behavioral phenotyping of transgenic and knockout mice: Experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res. 835: 18-26.
9. Desai, V. G., R. J. Feuers, R. W. Hart, and S. F. Ali. 1996. MPP(+)-induced neurotoxicity in mouse is age-dependent: Evidenced by the selective inhibition of complexes of electron transport. Brain Res. 715: 1-8.
10. Fornai, F., G. Battaglia, M. Gesi, F. S. Giorgi, F. Orzi, F. Nicoletti, and S. Ruggieri. 2000. Time-course and dose-response study on the effects of chronic L-DOPA administration on striatal dopamine levels and dopamine transporter following MPTP toxicity. Brain Res. 887: 110-117.
11. Fredriksson, A., and T. Archer. 1994. MPTP-induced behavioural and biochemical deficits: A parametric analysis. J. Neural Transm. Park. Dis. Dement. Sect. 7: 123-132.
12. Fredriksson, A., P. Eriksson, and T. Archer. 1997. MPTP-induced deficits in motor activity: Neuroprotective effects of the spintrapping agent, alpha-phenyl-tert-butyl-nitrone (PBN). J. Neural Transm. 104: 579-592.
13. Frey, K., M. Kilbourn, and T. Robinson. 1997. Reduced striatal vesicular monoamine transporters after neurotoxic but not after behaviorally-sensitizing doses of methamphetamine. Eur. J. Pharmacol. 334: 273-279.
14. Fuller, R. W., and S. K. Hemrick-Luecke. 1985. Mechanisms of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity to striatal dopamine neurons in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 9: 687-690.
15. Heikkila, R. E., and P. K. Sonsalla. 1992. The MPTP-treated mouse as a model of parkinsonism: How good is it? Neurochem. Int. 20(Suppl): 299S-303S.
16. Heikkila, R. E., A. Hess, and R. C. Duvoisin. 1984. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224: 1451-1453.
17. Heikkila, R. E., B. A. Sieber, L. Manzino, and P. K. Sonsalla. 1989. Some features of the nigrostriatal dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse. Mol. Chem. Neuropathol. 10: 171-183.
18. Hoskins, J. A., and L. J. Davis. 1989. The acute effect on levels of catecholamines and metabolites in brain, of a single dose of MPTP in 8 strains of mice. Neuropharmacology 28: 1389-1397.
19. Innis, R. B., J. P. Seibyl, B. E. Scanley, M. Laruelle, A. Abi-Dargham, E. Wallace, R. M. Baldwin, Y. Zea-Ponce, S. Zoghbi, and S. Wang, et al. 1993. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc. Natl. Acad. Sci. USA 90: 11965-11969.
20. Jackson-Lewis, V., M. Jakowec, R. E. Burke, and S. Przedborski. 1995. Time course and morphology of dopaminergic neuronal death caused by the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neurodegeneration 4: 257-269.
21. Kaufman, M. J., and B. K. Madras. 1991. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 9: 43-49.
22. Klapdor, K., B. G. Dulfer, A. Hammann, and F. J. Van der Staay. 1997. A low-cost method to analyse footprint patterns. J. Neurosci. Methods 75: 49-54.
23. Lee, E. H., and K. T. Lu. 1995. Neurotoxicity of MPTP and uptake of MPPT into dopamine and norepinephrine neurons in mice. Adv. Exp. Med. Biol. 363: 29-46.
24. Miller, G. W., J. K. Staley, C. J. Heilman, J. T. Perez, D. C. Mash, D. B. Rye, and A. I. Levey. 1997. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann. Neurol. 41: 530-539.
25. Miller, G. W., J. D. Erickson, J. T. Perez, S. N. Penland, D. C. Mash, D. B. Rye, and A. I. Levey. 1999. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156: 138-148.
26. Mitsumoto, Y., A. Watanabe, A. Mori, and N. Koga. 1998. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248: 660-663.
27. Naudon, L., I. Leroux-Nicollet, and J. Costentin. 1994. Short-term treatments with haloperidol or bromocriptine do not alter the density of the monoamine vesicular transporter in the substantia nigra. Neurosci. Lett. 173: 1-4.
28. Ogawa, N., Y. Hirose, S. Ohara, T. Ono, and Y. Watanabe. 1985. A simple quantitative bradykinesia test in MPTP-treated mice. Res. Commun. Chem. Pathol. Pharmacol. 50: 435-441.
29. Olsson, M., G. Nikkhah, C. Bentlage, and A. Bjorklund. 1995. Forelimb akinesia in the rat Parkinson model: Differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J. Neurosci. 15: 3863-3875.
30. Patel, S., and C. J. Hillard. 2001. Cannabinoid CB(1) receptor agonists produce cerebellar dysfunction in mice. J. Pharmacol. Exp. Ther. 297: 629-637.
31. Rozas, G., E. Lopez-Martin, M. J. Guerra, and J. L. Labandeira-Garcia. 1998. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J. Neurosci. Methods 83: 165-175.
32. Schallert, T., and J. L. Tillerson. 2000. Intervention strategies for degeneration of dopamine neurons in parkinsonism: Optimizing behavioral assessment of outcome. In Central Nervous System Diseases (D. F. Emerich, R. L. I. Dean, and P. R. Sanberg, Eds.), pp. 131-151. Humana Press, Totowa, NJ.
33. Schallert, T., I. Q. Whishaw, V. D. Ramirez, and P. Teitelbaum. 1978. Compulsive, abnormal walking caused by anticholinergics in akinetic, 6-hydroxydopamine-treated rats. Science 199: 1461-1463.
34. Sedelis, M., R. K. Schwarting, and J. P. Huston. 2001. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125: 109-125.
35. Seibyl, J. P., K. L. Marek, D. Quinlan, K. Sheff, S. Zoghbi, Y. Zea-Ponce, R. M. Baldwin, B. Fussell, E. O. Smith, and D. S. Charney, et al. 1995. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann. Neurol. 38: 589-598.
36. Spooren, W. P., A. Vassout, P. Waldmeier, and C. Gentsch. 1998. Differences in pre- and post-synaptic sensitivity to apo-morphine between saline and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57BL/6 mice as reflected in climbing activity. Eur. J. Pharmacol. 353: 1-4.
37. Sundstrom, E., A. Fredriksson, and T. Archer. 1990. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: A model for Parkinson's disease. Brain Res. 528: 181-188.
38. Sundstrom, E., I. Stromberg, T. Tsutsumi, L. Olson, and G. Jonsson. 1987. Studies on the effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on central catecholamine neurons in C57BL/6 mice. Comparison with three other strains of mice. Brain Res. 405: 26-38.
39. Tetrud, J. W. 1991. Preclinical detection of motor and nonmotor manifestations. Geriatrics 46(Suppl 1): 43-46.
40. Tillerson, J. L., A. D. Cohen, J. Philhower, G. W. Miller, M. J. Zigmond, and T. Schallert. 2001. Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine. J. Neurosci. 21: 4427-4435.
41. Tillerson, J. L., A. D. Cohen, W. M. Caudle, M. J. Zigmond, T. Schallert, and G. W. Miller. 2002. Forced non-use in unilateral parkinsonian rats exacerbates injury. J. Neurosci. 22: 6790-6799.
42. Vander Borght, T., M. Kilbourn, T. Desmond, D. Kuhl, and K. Frey. 1995a. The vesicular monoamine transporter is not regulated by dopaminergic drug treatments. Eur. J. Pharmacol. 294: 577-583.
43. Vander Borght, T. M., M. R. Kilbourn, R. A. Koeppe, J. N. DaSilva, J. E. Carey, D. E. Kuhl, and K. A. Frey. 1995b. In vivo imaging of the brain vesicular monoamine transporter. J. Nucl. Med. 36: 2252-2260.
44. Vila, M., S. Vukosavic, V. Jackson-Lewis, M. Neystat, M. Jakowec, and S. Przedborski. 2000. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74: 721-729.
45. Wang, Y. M., R. R. Gainetdinov, F. Fumagalli, F. Xu, S. R. Jones, C. B. Bock, G. W. Miller, R. M. Wightman, and M. G. Caron. 1997. Knockout of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron 19: 1285-1296.
46. Willis, G. L., and G. A. Donnan. 1987. Histochemical, biochemical and behavioural consequences of MPTP treatment in C-57 black mice. Brain Res. 402: 269-274.
47. Willis, G. L., M. K. Horne, and G. A. Donnan. 1988. Amine accumulation, catecholamine depletion and motor impairment in Macaca fasicularis and the C-57 black mouse after MPTP administration. Prog. Neuropsychopharmacol. Biol. Psychiatry 12: 469-482.
48. Zigmond, M. J., and E. M. Stricker. 1989. Animal models of parkinsonism using selective neurotoxins: Clinical and basic implications. Int. Rev. Neurobiol. 31: 1-79.